Antifungal and antidepressant drugs can effectively inhibit COVID-19 virus

NewsGuard 100/100 Score

New research published in the British Journal of Pharmacology indicates that two currently available medications--an antifungal drug and an antidepressant--can effectively inhibit the virus that causes COVID-19 in laboratory cells.

Investigators found that the antifungal itraconazole and the antidepressant fluoxetine each blocked the production of infectious SARS-CoV-2 virus in cell culture lab tests. When either drug was used in combination with the antiviral drug remdesiver, the combination showed synergistic effects and inhibited the production of SARS-CoV-2 by more than 90%.

Preventive vaccination and therapeutic medicines against COVID-19 are both required to effectively combat pandemics caused by emerging zoonotic viruses such as SARS-CoV-2."

Ursula Rescher, PhD, Study Senior Author, University of Muenster, Germany

Source:
Journal reference:

Schloer, S., et al. (2021) Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS‐CoV‐2 infection in vitro. British Journal of Pharmacology. doi.org/10.1111/bph.15418.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals high insomnia rates in non-hospitalized COVID-19 survivors